Loading...
Market
What will be Stryker's strategy for integrating Inari's products by March 31, 2025?
2
Resolution / Starting Odds
Full Integration • 25%
Partial Integration • 25%
Independent Operation • 25%
Discontinued Products • 25%
Company announcements, press releases, or financial reports
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80 Per Share, Targeting VTE Treatments
Jan 6, 2025, 08:22 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to expand Stryker's portfolio into the high-growth peripheral vascular segment, particularly targeting venous thromboembolism (VTE) treatments. Inari's innovative product offerings, which include mechanical thrombectomy solutions for conditions like deep vein thrombosis and pulmonary embolism, are seen as complementary to Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
More than 15% • 25%
5-10% • 25%
10-15% • 25%
Less than 5% • 25%
Yes • 50%
No • 50%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
Focus on cancer treatments • 25%
Focus on other areas • 25%
Focus on both equally • 25%
Focus on genetic engineering • 25%
Seek further trials • 25%
Partner with another company • 25%
Discontinue development • 25%
Submit for regulatory approval • 25%
Other strategic focus • 25%
Expansion of retail locations • 25%
Focus on digital transformation • 25%
Cost-cutting measures • 25%
Yes • 50%
No • 50%
Expansion in North America • 25%
Expansion in Latin America • 25%
Cost-cutting and restructuring • 25%
Focus on e-commerce growth • 25%
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%